INHIBIKASE THERAPEUTIC

Inhibikase Therapeutics Granted Pre-NDA Meeting with the FDA for IkT-001Pro

04 ديسمبر 2023 08:35:00 بحسب Nasdaq GlobeNewswire

Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Period Activity

14 نوفمبر 2023 16:30:06 بحسب Nasdaq GlobeNewswire

Correcting & Replacing -- Inhibikase Therapeutics to Report Third Quarter Financial Results on November 14, 2023

07 نوفمبر 2023 09:28:32 بحسب Nasdaq GlobeNewswire

Inhibikase Therapeutics to Report Second Quarter Financial Results on November 14, 2023

07 نوفمبر 2023 08:00:01 بحسب Nasdaq GlobeNewswire

Inhibikase Therapeutics Highlights Unblinded Functional Analysis from the 201 Trial of Risvodetinib in Untreated Parkinson’s Disease and Provides Update on Ongoing Enrollment

16 أكتوبر 2023 07:00:27 بحسب Nasdaq GlobeNewswire

Inhibikase Therapeutics Receives FDA Orphan Drug Designation for Risvodetinib for the Treatment of Multiple System Atrophy

04 أكتوبر 2023 08:30:00 بحسب Nasdaq GlobeNewswire